3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
1
Multiple Myeloma
1
Mouth Neoplasms
1
Laryngeal Diseases
1
Hodgkin Disease
1
Hepatoblastoma
1
Glioblastoma
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
dostarlimab
×
Clear all
NCT04837209
2025-10-01
NADiR
Massachusetts General Hospital
Phase 2
Active not recruiting
32 enrolled